Aptus Capital Advisors’s United Therapeutics UTHR Stock Holding History

Aptus Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-415	Closed	-$246K	–	1846
2026 Q1	$246K	Sell	415 -47	-10%	-$23.4K	﹤0.01%	940
2025 Q4	$225K	Buy	+462	New	+$215K	﹤0.01%	997
2023 Q1	–	Sell	-2,415	Closed	-$672K	–	899
2022 Q4	$672K	Sell	2,415 -671	-22%	-$169K	0.02%	315
2022 Q3	$646K	Buy	+3,086	New	+$690K	0.02%	297
2019 Q4	–	Sell	-16,879	Closed	-$1.35M	–	570
2019 Q3	$1.35M	Buy	16,879 +2,059	+14%	+$166K	0.08%	157
2019 Q2	$1.16M	Buy	14,820 +363	+3%	+$33.9K	0.16%	120
2019 Q1	$1.7M	Buy	14,457 +1,282	+10%	+$149K	0.29%	82
2018 Q4	$1.43M	Buy	+13,175	New	+$1.53M	0.38%	43

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Aptus Capital Advisors's UTHR Position: Q2 2026 in Review

Aptus Capital Advisors sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 415 shares — an estimated $246K sold.

Aptus Capital Advisors first reported a position in UTHR in Q4 2018 and held it in 8 quarters. The position peaked at $1.7M in Q1 2019. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Aptus Capital Advisors reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Aptus Capital Advisors sold 415 United Therapeutics shares in Q2 2026, an estimated $246K.
Aptus Capital Advisors first reported a position in United Therapeutics in Q4 2018 and held it in 8 quarters.
Aptus Capital Advisors's United Therapeutics position peaked at $1.7M in Q1 2019.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.